Bibliography: Skin & Oncology
ESKIMO Group Recommendations
- Dreno B., Bensadoun R.J., Humbert P., et al. Guidance from the ESKIMO Group recommendations: an algorithm for dermocosmetic use in the management of cutaneous side effects associated with targeted therapy in oncology.
Cutaneous toxicity of anticancer-targeted therapy is common and becomes a substantial problem for both patients and caregivers, which may result in poor compliance. To help improving the management of the targeted therapy related-cutaneous side effects, a European group of experts (ESKIMO group) built an algorithm for the appropriate use of dermatological cosmetics …
Read the poster
Download the free full text publication
Skin & Cancer Treatments Clinical Studies
- Lüftner D, Dell'Acqua V, Selle F, Khalil A, Leonardi MC, De La Torre Tomás A, Shenouda G, Romero Fernandez J, Orecchia R, Moyal D, Seité S. Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy. 2018 Sep 17;11:5865-5872. doi: 10.2147/OTT.S155438. eCollection 2018.
Read the abstract
Video: Evaluation of supportive and barrier-protective skin care products
- Seité S, Bensadoun RJ, Mazer JM. Prevention and treatment of acute and chronic radiodermatitis. 2017 Nov 2;9:551-557. doi: 10.2147/BCTT.S149752. eCollection 2017.
Read the abstract
Video: Prevention and treatment of acute and chronic radiodermatitis
- Wohlrab J., Richter R., Seite S., Lüftner D. Barrier protective skin care for prophylaxis of chemotherapy-induced cutaneous symptoms.
This prospective, open, randomized, controlled, cross-over, multicenter, interventional study, conducted in patients with breast cancer undergoing chemotherapy, has evaluated the efficacy on QoL of a 4% niacinamide lipophilic cream…
Read the poster
Download the free full text publication - Berger A., Regueiro C., Hijal T., et al. Evaluation of non-pharmaceutical skin-care products in the daily prevention, treatment and palliative care of skin toxicity during radiotherapy.
To evaluate the tolerability and interest in the use of dermo-cosmetic products from La Roche-Posay in the prevention of radiotherapy-induced cutaneous side effects, this multicenter observational study was conducted in 253 women treated for breast cancer…
Read the poster - Dell’Acqua V., Lüftner D., Selle F., et al. Evaluation of non-pharmaceutical skin-care products in the daily prevention, treatment and palliative care of skin toxicity during chemotherapy.
One hundred and forty-seven male and female, treated by chemotherapy in 5 cancer units (4 in Europe, one in Canada) were included in this observational study conducted to evaluate tolerability and interest of La Roche-Posay dermo-cosmetic products in the prevention of chemotherapy-induced cutaneous side effects…
Read the poster - Demarch E.B., Towersey L., Lobo M.K., et al. A cream containing lipohydroxy acid as a new alternative treatment for cetuximab-induced papulopustular eruption.
In this case-report, a patient treated for metastatic colon cancer developed a cetuximab-induced papulopustular eruption and showed a favorable response to the use of a cream containing lipohydroxy acid, salicylic acid, niacinamide and piroctone olamine.
Read the poster - Peuvrel L., Vallet C., Quereux G., et al. Evaluation of quality of life after a medical corrective make-up lesson in patients with various dermatoses.
To evaluate the evolution of quality of life one month after a medical corrective make-up consultation, this large French study was conducted in 177 patients with various skin diseases including acne, scars of cancer, pigmentary disorders, chemotherapy adverse events…
Read the poster - Ainouche R., Lesrel C., Seite S., et al. Post cancer cure at La Roche-Posay: an update on observational studies.
In 2010 and 2012, 3 studies were conducted in patients following a post cancer thermal cure at La Roche-Posay to evaluate the effects of this dermatological thermal cure: In terms of tolerance, satisfaction and benefits in 102 patients previously treated for cancer; In terms of functional recovery in 53 patients in remission and suffering from functional problems of the upper limb following breast cancer treatment; In terms of benefit in quality of life, following treatment for pain and mobility of the area affected by surgery in 51 patients.
Read the poster - Gelot P., Dutartre H., Khammari A., et al. Vemurafenib: an unusual UVA-induced photosensitivity.
This study aimed to characterize precisely vemurafenib-induced photosensitivity and to determine whether daily protective moisturizer SPF 50+ UVA-PF 40 could prevent it…
Read the poster
Download the free full text publication - Dummer R., Rinderknecht J., Goldfinger S.M. Ultraviolet A and photosensitivity during vemurafenib therapy.
To advise the most appropriate photoprotection measures to prevent vemurafenid-induced photoxicity, the authors’ objective was to identify the responsible ultraviolet spectrum…
Read the poster
Cutaneous side effects of cancers's treatments and their management
- American Cancer Society. Side Effects of Targeted Cancer Therapy Drugs. (last visit: 12/12/17)
American Cancer Society website
- Bensadoun R-J., Humbert P., Krutman J., et al. Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel. Can Manag Res. 2013;5:401-8.
Link to download the free full text - Bolderston A., Lloyd N.S., Wong R.K.S. et al. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer 2006;14(8):802-17.
Link to the abstract - Burtness B., Anadkat M., Basti S., et al. NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer. J Natl Compr Canc Netw. 2009;7(Suppl 1):S5-18.
Link to the abstract - Cancer Net. Skin Reactions to Targeted Therapy and Immunotherapy. (last visit: 12/12/17)
Cancer.Net website - Fabbrocini G., Cameli N., Romano M.C., et al. Chemotherapy and skin reactions. J Exp Clin Cancer Res. 2012;31(1):50.
Link to download the free full text
- Lacouture M.E., Anadkat M.J., Bensadoun R-J., et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011;19:1079–95.
Link to download the free full text - Lupu I., Voiculescu V.M., Bacalbasa N., et al. Cutaneous complications of molecular targeted therapy used in oncology. J Med Life 2016;9(1):19-25.
Link to download the free full text - Ouwerkerk J., Boers-Doets C. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs 2010; 14: 337–349
Link to download the free full text - Perez-Soler R., Saltz L. Cutaneous adverse events with HER1/EGFRtargeted agents: is there a silver lining? J Clin Oncol 2005;23:5235–46.
Link to download the free full text - Robert C., Soria J-C., Spatz A., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6: 491–500.
Link to the abstract - Salvo N., Barnes E., van Draanen J., et al. Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature. Current Oncology 2010;17(4):94-112.
Link to download the free full text - Seité S., Bensadoun R-J., Mazer J-M. Prevention and treatment of acute and chronic radiodermatitis. Breast Cancer - Targets and Therapy 2017;9:551–57.
Link to download the free full text - Stanculeanu D.L., Zob D., Toma O.C., et al. Cutaneous toxicities of molecular targeted therapies. Medica 2017;12(1):48-54.
Link to download the free full text